In a recent interview with Drug Development & Delivery, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, shared insights into the company’s innovative approach to treating central nervous system (CNS) and solid tumor cancers using targeted radiotherapeutics.
Unlike conventional external beam radiation therapy, Plus Therapeutics is pioneering internal radiation delivery methods designed for precision treatment and greater efficacy. By delivering radiotherapeutic agents directly to the tumor site, this approach can minimize damage to healthy tissue and potentially improve patient outcomes.
Dr. Hedrick explained how this platform technology—backed by multiple ReSPECT clinical trials—is built to meet the needs of patients with some of the most difficult-to-treat cancers, including glioblastoma and leptomeningeal metastases.
“We believe targeted radiotherapeutics offer the potential for safer, more effective treatment—especially when delivery is optimized for the brain and spinal cord,” said Dr. Hedrick in the Q&A.
Read the full Q&A here
Learn more about our RESPECT clinical trials
#PSTV #Radiotherapeutics #Radiotherapy #ClinicalTrials #DrugDelivery #NeuroOncology #SolidTumors #CNSCancers #PrecisionMedicine #InternalRadiation #ReSPECTTrials
Recent Comments